Silexion Therapeutics Corp
SLXNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $70.3K in total; no superinvestor holds it.
Other share classesSLXN
13F holders, Q2 2025
Institutional positions in Silexion Therapeutics Corp as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −3 vs. Q1 2025
- Shares held
- 2.66M
- −313 (0.0%) vs. Q1 2025
- Total value
- $107.6K
- −$91.5K (−45.9%) vs. Q1 2025
- New holders
- 0
- 3 more added
- Sold out
- 3
- 2 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLXNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $70.3K |
| Q1 2026 | 19 | $47.7K |
| Q4 2025 | 22 | $61.8K |
| Q3 2025 | 22 | $89.8K |
| Q2 2025 | 22 | $107.6K |
| Q1 2025 | 25 | $199.1K |
| Q4 2024 | 26 | $91.7K |
| Q3 2024 | 32 | $106.1K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Silexion Therapeutics Corp; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 743,475 | $30.4K | 0.00% | 00.0% | Unchanged |
| Linden Advisors LP | 337,500 | $14.0K | 0.00% | 00.0% | Unchanged |
| Aristeia Capital LLC | 236,546 | $9.78K | 0.00% | 00.0% | Unchanged |
| Clear Street LLC | 219,765 | $8.99K | 0.00% | +74,600+51.4% | Added |
| Hartree Partners, LP | 182,355 | $7.29K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 150,982 | $5.75K | 0.00% | +99,181+191.5% | Added |
| Security Benefit Life Insurance Co | 150,000 | $5.71K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 113,568 | $4.64K | 0.00% | +3,476+3.2% | Added |
| Kepos Capital LP | 100,000 | $4.00K | 0.01% | 00.0% | Unchanged |
| Jane Street Group, LLC | 74,910 | $3.06K | 0.00% | −392−0.5% | Reduced |
| Context Capital Management, LLC | 51,183 | $2.09K | 0.00% | 00.0% | Unchanged |
| Tenor Capital Management Co., L.P. | 50,000 | $2.04K | 0.00% | 00.0% | Unchanged |
| Picton Mahoney Asset Management | 57,175 | $2.00K | 0.00% | 00.0% | Unchanged |
| Gabelli & Co Investment Advisers, Inc. | 38,150 | $1.56K | 0.00% | 00.0% | Unchanged |
| Neuberger Berman Group LLC | 31,552 | $1.29K | 0.00% | 00.0% | Unchanged |
| Gabelli Funds LLC | 30,496 | $1.25K | 0.00% | 00.0% | Unchanged |
| DuPont Capital Management Corp | 32,500 | $1.24K | 0.00% | 00.0% | Unchanged |
| Mint Tower Capital Management B.V. | 25,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Stifel Financial Corp | 16,000 | $654 | 0.00% | 00.0% | Unchanged |
| Saba Capital Management, L.P. | 11,937 | $488 | 0.00% | 00.0% | Unchanged |
| Cobblestone Capital Advisors LLC | 10,000 | $409 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 100 | $4 | 0.00% | −10−9.1% | Reduced |
| Periscope Capital Inc. | 0 | $0 | 0.00% | −87,169−100.0% | Sold out |
| Yakira Capital Management, Inc. | 0 | $0 | 0.00% | −75,000−100.0% | Sold out |
| Rivernorth Capital Management, LLC | 0 | $0 | 0.00% | −14,999−100.0% | Sold out |